Intervacc AB (publ)

Stockholm Stock Exchange IVACC.ST

Intervacc AB (publ) Capital Expenditure for the year ending December 31, 2023: USD -207.96 K

Intervacc AB (publ) Capital Expenditure is USD -207.96 K for the year ending December 31, 2023, a 64.49% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Intervacc AB (publ) Capital Expenditure for the year ending December 31, 2022 was USD -585.61 K, a 77.08% change year over year.
Intervacc AB (publ) Capital Expenditure for the year ending December 31, 2021 was USD -2.55 M, a -84.63% change year over year.
Intervacc AB (publ) Capital Expenditure for the year ending December 31, 2020 was USD -1.38 M, a 67.07% change year over year.
Intervacc AB (publ) Capital Expenditure for the year ending December 31, 2019 was USD -4.20 M, a -53.26% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Stockholm Stock Exchange: IVACC.ST

Intervacc AB (publ)

CEO	Mr. Jonas Sohlman
IPO Date	April 7, 2017
Location	Sweden
Headquarters	Västertorpsvägen 135
Employees	15
Sector	Healthcare
Industries Vaccines Biotechnology Pet Food Pharmaceuticals

Description

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.

Key trends

Past 5 years